[Natalizumab and atypical naevi: Comments on the pharmacovigilance note by J.-L. Schmutz et al].
Yaldizli
O
O
Baumberger
P
P
Putzki
N
N
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D008545:Melanoma / Q000188:drug therapy; D000069442:Natalizumab; D009506:Nevus / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab